Regardless of prior treatment , all patients in this study received subcutaneous 60-mg tabalumab Q4W for the first 3months , then a one-time increase to 120-mg tabalumab Q4W ( 60-mg/120-mg group ) and a one-time decrease to 60-mg tabalumab Q4W per patient was allowed ( 60-mg/120-mg/60-mg group ) .